Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07037459 · ClinicalTrials.gov registry record · Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
A Phase 3 study of Obesity and Heart Failure With Preserved Ejection Fraction, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 5,056
- Enrollment target
- 20
- Study locations
NCT07037459 is a Phase 3 study of Obesity and Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by Amgen. The registered enrollment target is 5,056 participants, above the 814-participant average among 1,053 other Obesity trials with a reported enrollment target (521% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT07037459, a Phase 3 study of Obesity and Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 5,056 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maridebart cafraglutide
Study Locations (20)
California
- National Heart Institute - Beverly Hills
- Valley Clinical Trials, LLC dba Flourish Research - Covina
- National Institute of Clinical Research - Huntington Beach
- 310 Clinical Research - Inglewood
- Radin Cardiovascular Medical Group - Newport Beach
- Valley Clinical Trials - Northridge
- University of California Irvine - Orange
- Empire Clinical Research - Pomona
- San Diego Cardiac Center - San Diego
- NorthBay Clinical Research LLC - Santa Rosa
- Manshadi Heart Institute - Stockton
Alabama
- University of Alabama at Birmingham - Birmingham
- SEC Clinical Research - Dothan
- Eastern Shore Research Institute - Fairhope
- Heart Center Research LLC - Huntsville
Arizona
- HonorHealth - Phoenix
- Medical Advancement Centers of Arizona - Phoenix
- Pima Heart and Vascular Clinical Research - Tucson
- Yuma Clinical Trials - Yuma
Arkansas
- Arkansas Cardiology - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,056 participants |
| Start Date | 2025-06-25 |
| Est. Completion | 2030-09-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07037459
The ClinicalTrials.gov registry entry for NCT07037459 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 5,056 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 814-participant average among 1,053 other Obesity trials with a reported enrollment target (521% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07037459 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT07037459 about?
NCT07037459 is a clinical study titled "Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity". This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fract...
What is the current status of trial NCT07037459?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,056 participants. The study started on 2025-06-25. Estimated completion is 2030-09-29.
What conditions does trial NCT07037459 study?
This clinical trial studies the following conditions: Obesity, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction.
What interventions are being tested in trial NCT07037459?
The interventions under investigation include: Placebo (DRUG), Maridebart cafraglutide (DRUG).
Who is sponsoring clinical trial NCT07037459?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07037459 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.